Role of c-Myc in lung cancer: Progress, challenges, and prospects.
Role of c-Myc in lung cancer: Progress, challenges, and prospects.
复制标题
DOI：
10.1016/j.pccm.2023.07.001
复制
发表时间：
2023-09
期刊：
影响因子：
--
通讯作者：
Lu, Hua
中科院分区：
文献类型：
--
作者：
Wallbillich, Nicholas J;Lu, Hua
肺癌仍然是全世界癌症相关死亡的主要原因。尽管最近癌症治疗取得了进展，但非小细胞肺癌（NSCLC）患者的5年生存率徘徊在20%左右。固有耐药和获得性耐药（包括放疗、化疗、靶向药物和联合治疗）已成为成功治疗非小细胞肺癌的重要障碍。c-Myc是一种关键的癌蛋白，已被证明与恶性肿瘤表型密切相关，包括多种癌症类型的快速增殖、转移和化疗耐药。c-Myc原癌基因在小细胞肺癌（SCLCs）中扩增，在超过50%的nsclc中过表达。已知c-Myc积极调节癌症干细胞基因的转录，这些基因被认为是肿瘤进展和治疗耐药性的主要贡献者；因此，直接或间接地靶向c-Myc以减轻癌症干性表型成为开发抗耐药肺癌新策略的有希望的方法。本文将总结目前已知的c-Myc调控肿瘤干细胞及其参与耐药的机制，并对目前在SCLC和NSCLC中靶向治疗c-Myc的进展和未来前景进行概述。
Lung cancer remains the leading cause of cancer-related deaths worldwide. Despite the recent advances in cancer therapies, the 5-year survival of non-small cell lung cancer (NSCLC) patients hovers around 20%. Inherent and acquired resistance to therapies (including radiation, chemotherapies, targeted drugs, and combination therapies) has become a significant obstacle in the successful treatment of NSCLC. c-Myc, one of the critical oncoproteins, has been shown to be heavily associated with the malignant cancer phenotype, including rapid proliferation, metastasis, and chemoresistance across multiple cancer types. The c-Myc proto-oncogene is amplified in small cell lung cancers (SCLCs) and overexpressed in over 50% of NSCLCs. c-Myc is known to actively regulate the transcription of cancer stemness genes that are recognized as major contributors to tumor progression and therapeutic resistance; thus, targeting c-Myc either directly or indirectly in mitigation of the cancer stemness phenotype becomes a promising approach for development of a new strategy against drug resistant lung cancers. This review will summarize what is currently known about the mechanisms underlying c-Myc regulation of cancer stemness and its involvement in drug resistance and offer an overview on the current progress and future prospects in therapeutically targeting c-Myc in both SCLC and NSCLC.